|
 Cancer medicines were a highlight, including demand for Imfinzi,
following U.S. approval of the immunotherapy in early lung cancer,
and Chief Executive Pascal Soriot said the company remained on track
for a return to product sales growth in 2018.
"Clearly, our strategy is working," he told reporters. "It's been a
long journey for us, rebuilding our pipeline and launching new
products, but we are starting to see the fruits of this hard work."
China was once again a bright spot, as AstraZeneca continues to
outperform competitors in the world’s second biggest drugs market,
where it is using digital apps and other healthcare technology to
help sell its medicines.
Investors cheered growing evidence of the British drugmaker's
recovery, pushing the shares up more than 2 percent on Thursday.
Analysts said they were also encouraged by better than expected
second-quarter profit margins, which reversed a trend seen in the
first quarter.
The brighter outlook comes at a time of mounting criticism of high
drug prices by U.S. President Donald Trump, which Soriot sought to
deflect by joining other companies in promising a pricing freeze for
the remainder of 2018.
AstraZeneca's total revenue increased 2 percent in dollar terms in
the second quarter to $5.16 billion, although core earnings per
share, which exclude some items, fell 21 percent to 69 cents,
reflecting investment behind new product launches.
Analysts, on average, had forecast earnings of 71 cents on revenue
of $5.16 billion, Thomson Reuters data showed. For the full year,
the company kept its financial guidance unchanged.
$1 BILLION OF NEW MEDICINES
Drug sales in the three months rose 2 percent, helped by a weaker
dollar, but were down 1 percent in constant currencies, which is the
benchmark AstraZeneca uses for measuring its return to growth.
New medicines, however, generated more than $1 billion of additional
sales over the first half of the year, growing 75 percent in dollar
terms or 69 percent at constant currencies.
[to top of second column] |
For 2018 as a whole, AstraZeneca expects a low single-digit
percentage increase in overall product sales in constant currencies
and core earnings per share of $3.30 to $3.50.
The drugmaker has suffered the industry's biggest patent cliff since
2012, wiping out more than half of its sales, but analysts' now
believe it is poised for one of the sector's fastest growth rates in
the coming years.
Key to this are new cancer pills Tagrisso and Lynparza, as well as
the infused treatment Imfinzi, which has stolen a march on
established immunotherapies from Merck, Bristol-Myers Squibb and
Roche that are focused on advanced disease.
All three cancer drugs beat analysts' forecasts for quarterly sales,
as did AstraZeneca's new biotech asthma treatment Fasenra.
Following the U.S. green light for Imfinzi in February, the European
Medicines Agency is also evaluating it in inoperable stage III lung
cancer - where disease has not yet spread around the body - and
could recommend it as early as this week.
AstraZeneca's re-emergence as a drug company with a strong pipeline
of new medicines contrasts with the story at British rival
GlaxoSmithKline , which is just starting out on a program to reboot
its drug discovery efforts.
For the graphic 'AstraZeneca outperforms GlaxoSmithKline', click -
https://reut.rs/2JX1upI
(Reporting by Ben Hirschler; Editing by Susan Fenton and Elaine
Hardcastle)
[© 2018 Thomson Reuters. All rights
reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
 |
